Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

OTHER 2 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 23 Carcinoma, Transitional Cell 15 Neoplasms 14 Ovarian Neoplasms 13 Carcinoma, Renal Cell 13 Urinary Bladder Neoplasms 12 Carcinoma, Merkel Cell 12 Squamous Cell Carcinoma of Head and Neck 11 Colorectal Neoplasms 8 Triple Negative Breast Neoplasms 7 Pancreatic Neoplasms 7 Neoplasm Metastasis 7 Melanoma 7 Stomach Neoplasms 6 Recurrence 5 Breast Neoplasms 5 Carcinoma, Hepatocellular 3 Uterine Cervical Neoplasms 2 Small Cell Lung Carcinoma 2 Sarcoma 2 Lymphoma, Non-Hodgkin 2 Kidney Neoplasms 2 Kidney Diseases 2 Head and Neck Neoplasms 2 Fallopian Tube Neoplasms 2 Central Nervous System Neoplasms 2 Carcinoma, Squamous Cell 2 Carcinoma, Ovarian Epithelial 2 Uveal Melanoma 1 Urothelial Cancer 1

Interventions

Carboplatin 30 Cisplatin 23 pembrolizumab 22 Paclitaxel 21 Pemetrexed 20 Gemcitabine 10 osimertinib 9 durvalumab 9 Nivolumab 9 130-nm albumin-bound paclitaxel 8 Sunitinib 7 Sorafenib 7 Fluorouracil 7 Everolimus 7 Docetaxel 7 Axitinib 7 Cetuximab 6 epothilone B 5 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 5 volociximab 4 trebananib 4 reolysin 4 catumaxomab 4 cabozantinib 4 atezolizumab 4 Radiotherapy 4 Ipilimumab 4 vosaroxin 3 liposomal doxorubicin 3 lenvatinib 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Carcinoma × avelumab × Clear all

NCT03268057 2022-05-02

CLASSICAL-Lung

Vaccinex Inc.

Phase 1/2 Completed

Carcinoma, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon ⚡